What is Altimmune's operating income?

Altimmune (ALT) reported operating income of -$24.24M in Q1 2026.

How has Altimmune's operating income changed year-over-year?

Altimmune's operating income decreased by 11.1% year-over-year, from -$21.82M to -$24.24M.

What is the long-term trend for Altimmune's operating income?

Over 4 years (2021 to 2025), Altimmune's operating income has grown at a -0.6% compound annual growth rate (CAGR), from -$96.91M to -$94.49M.

What does operating income mean?

Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Altimmune ALT Operating Income

Operating Income at other companies

Madrigal Pharmaceuticals, Inc.MDGL

-$92.72M-16.9%

Viking TherapeuticsVKTX

-$164.13M-196%

Wave Life SciencesWVE

-$31.3M+37.2%

MeiraGTx Holdings plcMGTX

-$40.82M+1.9%

Avalo TherapeuticsAVTX

-$20.9M-42.5%

Mirum Pharmaceuticals, Inc.MIRM

-$789.47M-5,100%

Other financials

Income statement

See full

Revenue$26.0K+420%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's operating income?: Altimmune (ALT) reported operating income of -$24.24M in Q1 2026.
How has Altimmune's operating income changed year-over-year?: Altimmune's operating income decreased by 11.1% year-over-year, from -$21.82M to -$24.24M.
What is the long-term trend for Altimmune's operating income?: Over 4 years (2021 to 2025), Altimmune's operating income has grown at a -0.6% compound annual growth rate (CAGR), from -$96.91M to -$94.49M.
What does operating income mean?: Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.